Observational studyBMC infectious diseases2026
Azathioprine for remission maintenance in anti-interferon-γ autoantibody-associated immunodeficiency syndrome- a retrospective single-center cohort study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-interferon-γ autoantibody (Anti-IFN-γ Aab) disease is associated with frequent recurrent infections. Adjunctive immunosuppressive treatment, including rituximab, can achieve disease remission. However, disease relapses and recurrent infections occur after immunosuppressive drugs are discontinued. Azathioprine (AZA) is used for maintenance therapy in many autoimmune diseases with few adverse effects. This study aimed to assess the effectiveness of AZA in maintaining clinical remission in patients with Anti-IFN-γ Aab disease.
methodsThis retrospective observational study was conducted at Ramathibodi Hospital, Thailand, from 2019 to 2023. The study involved two patient groups with Anti-IFN-γ; Aab disease who received maintenance therapy with AZA and without AZA, respectively. The patients' demographics, clinical disease courses, and other relevant information were collected.
resultsOf the 29 sampled patients, 15 received AZA maintenance therapy, and 14 did not. There were no notable differences between the groups regarding demographics (age and sex), clinical presentation, identified pathogens, and infection episodes before initiating immunosuppressive treatment or the induction regimen. The Kaplan-Meier 50% cumulative survival analysis of disease relapse time was 3.99 years in the AZA group compared to 0.88 years in the group without AZA. The covariate-adjusted survival curve estimations of the durations of antimicrobial treatments, Anti-IFN-γ Aab inhibition titers before AZA initiation, and induction regimens showed a hazard ratio of 0.096 (p=0.006, 95%CI: 0.018-0.507) in the AZA group.
conclusionAZA was generally safe and associated with prolonged remission in Anti-IFN-γ; Aab disease and reducing relapse rates, despite the occurrence of some breakthrough infections. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.